X4 Pharmaceuticals, Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.1 | $2.6 | $0.0 | $0.0 | $0.0 |
| Operating income | -$86.9 | -$36.4 | -$107.5 | -$87.6 | -$85.1 |
| Net income | -$79.2 | -$37.5 | -$101.2 | -$93.9 | -$88.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$85.6 | -$131.2 | -$96.6 | -$77.2 | -$71.5 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Share repurchases | — | — | $0.0 | $0.0 | $2.0 |
Shares outstanding 99.1M · Free float 78.4%
Annual filing data through FY ended December 31, 2025; float as of October 12, 2026.
X4 Cuts 4WARD Enrollment Target After FDA Alignment